Orbimed Advisors Trims $125 After Breakout Year in Biotech
A major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
Discover brokers offering index funds, focusing on accessibility, fees, and customer experience to pick the best platform.
24,222 articlesA major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
A major fund exits a Buckle stake, triggering questions about strategy and market signals. This article breaks down w...
Ken Griffin, the Citadel founder once openly skeptical of AI, has pivoted to embracing its potential, telling audienc...
Craving a position in SpaceX before it goes public? An ETF that blends public and late-stage private exposure, like X...
A New York man was sentenced to 15 months in federal prison for running a Telegram-based crypto fraud that netted abo...
A routine phone call turned a family’s finances upside down when a grandmother thought grandson needed help and the s...
A major fund trims a big stake in a tech name, sparking questions about risk, sector exposure, and portfolio resilien...
As geopolitical tensions rise, investors reassess defense exposure. This report examines the weapons that changed war...
As Treasury yields swing this spring, many in the top tax bracket are choosing tax-free municipal bonds. A fund model...
Trump hints at government equity in AI leaders, echoing Bernie Sanders and roiling MAGA voters as markets weigh how A...
The eVTOL craze mixes hype with real engineering, regulatory hurdles, and capital burn. Here's why I wouldn't touch t...
Federal prosecutors say a California couple ran a crypto-laundering operation tied to darknet fentanyl shipments, mov...